These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16918471)

  • 1. Application of support vector machines to in silico prediction of cytochrome p450 enzyme substrates and inhibitors.
    Yap CW; Xue Y; Li ZR; Chen YZ
    Curr Top Med Chem; 2006; 6(15):1593-607. PubMed ID: 16918471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines.
    Yap CW; Chen YZ
    J Chem Inf Model; 2005; 45(4):982-92. PubMed ID: 16045292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational models for predicting interactions with cytochrome p450 enzyme.
    Arimoto R
    Curr Top Med Chem; 2006; 6(15):1609-18. PubMed ID: 16918472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families.
    Lewis DF
    Curr Med Chem; 2003 Oct; 10(19):1955-72. PubMed ID: 12871098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.
    Lewis DF
    Biochem Pharmacol; 2000 Aug; 60(3):293-306. PubMed ID: 10856424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.
    Kriegl JM; Arnhold T; Beck B; Fox T
    J Comput Aided Mol Des; 2005 Mar; 19(3):189-201. PubMed ID: 16059671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship for human cytochrome P450 substrates and inhibitors.
    Lewis DF; Modi S; Dickins M
    Drug Metab Rev; 2002; 34(1-2):69-82. PubMed ID: 11996013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico modeling of p450 substrates, inhibitors, activators, and inducers.
    DeLisle RK; Otten J; Rhodes S
    Comb Chem High Throughput Screen; 2011 Jun; 14(5):396-416. PubMed ID: 21470185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
    Kalgutkar AS; Obach RS; Maurer TS
    Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
    Di L; Kerns EH; Li SQ; Carter GT
    Int J Pharm; 2007 Apr; 335(1-2):1-11. PubMed ID: 17137735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.
    Crivori P; Poggesi I
    Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds.
    Cheng F; Yu Y; Zhou Y; Shen Z; Xiao W; Liu G; Li W; Lee PW; Tang Y
    J Chem Inf Model; 2011 Oct; 51(10):2482-95. PubMed ID: 21875141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of drug metabolism: the case of cytochrome P450 2D6.
    Vermeulen NP
    Curr Top Med Chem; 2003; 3(11):1227-39. PubMed ID: 12769702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design.
    Rekka EA; Kourounakis PN; Pantelidou M
    Curr Top Med Chem; 2019; 19(4):276-291. PubMed ID: 30706817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrochemical investigations of cytochrome P450.
    Shumyantseva VV; Bulko TV; Suprun EV; Chalenko YM; Vagin MY; Rudakov YO; Shatskaya MA; Archakov AI
    Biochim Biophys Acta; 2011 Jan; 1814(1):94-101. PubMed ID: 20650335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of human cytochrome P450 2B6-substrate interactions using hierarchical support vector regression approach.
    Leong MK; Chen YM; Chen TH
    J Comput Chem; 2009 Sep; 30(12):1899-909. PubMed ID: 19115281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.
    Venkatakrishnan K; Von Moltke LL; Greenblatt DJ
    J Clin Pharmacol; 2001 Nov; 41(11):1149-79. PubMed ID: 11697750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational methods and tools to predict cytochrome P450 metabolism for drug discovery.
    Tyzack JD; Kirchmair J
    Chem Biol Drug Des; 2019 Apr; 93(4):377-386. PubMed ID: 30471192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QSAR of cytochrome inhibitors.
    Roy K; Roy PP
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1245-66. PubMed ID: 19708826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A; Komorowski J; Wikberg JE
    J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.